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Abstract
 
Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) is a cell surface
molecule that has been proposed to negatively regulate T cell function. We have shown that
CEACAM1 is associated with specific regulation of T helper cell (Th)1 pathways, T-bet–
mediated Th1 cytokine signaling, and Th1-mediated immunopathology in vivo. Mice treated
with anti–mouse CEACAM1-specific monoclonal antibody (mAb) CC1 during the effector
phase exhibited a reduced severity of trinitrobenzene sulfonic acid colitis in association with
decreased interferon (IFN)-
 
  
 
production. Although oxazolone colitis has been reported as Th2
mediated, mice treated with the CC1 mAb or a CEACAM1-Fc chimeric protein exhibited a
 
reduced severity of colitis in association with a significant reduction of IFN-
 
  
 
and T-bet activation,
whereas signal transducer and activator of antigen 4 activation was unaffected. Both interleukin-4
 
and IFN-
 
  
 
gene–deficient mice exhibited less severe colitis induction by oxazolone. Direct
ligation of T cells in vitro with the murine hepatitis virus spike protein, a natural ligand for the
N-domain of CEACAM1, inhibited the differentiation of naive cells into Th1 but not Th2
cells and activation of Th1 but not Th2 cytokine production. These results indicate that
CEACAM1 isoforms are a novel class of activation-induced cell surface molecules on T cells
that function in the specific regulation of Th1-mediated inflammation such as that associated
with inflammatory bowel disease.
Key words: CEACAM1 • inﬂammatory bowel disease • hapten-induced colitis • 
T cell immunity • Th1 cytokine
 
Introduction
 
Carcinoembryonic antigen-related cellular adhesion mole-
cule 1 (CEACAM1; also known as CD66a or biliary gly-
coprotein) is a member of the carcinoembryonic antigen
family of glycoproteins with homologues in rodents (mice
and rats) and humans (1, 2). CEACAM1 is expressed in a
wide variety of organs and cell types including a variety of
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epithelial and hematopoietic cell lineages (NK cells, B
cells, polymorphonuclear leukocytes, monocytes, and
DCs; 2–7). The extracellular domain of CEACAM1 iso-
forms consists of a membrane distal IgV-like N-domain
followed by variable numbers of alternating IgI1 and IgI2
set domains with either a long or short cytoplasmic tail (1,
8). In mice, two alleles of CEACAM1 exist (a and b)
based upon differences in the N-domain. Most mouse
strains express the “a” allele (1). The long, 73–amino acid
cytoplasmic tail of CEACAM1 contains two immunore-
ceptor tyrosine-based inhibitory motifs (ITIMs) that
have been shown to negatively regulate cellular activa-
tion in epithelial cells (2, 9). This inhibitory property of
CEACAM1 is triggered by phosphorylation of tyrosine
residues within the ITIMs resulting in recruitment of the
Src homology 2 domain–containing tyrosine phosphatases
SHP-1 and SHP-2 and the Src homology 2–containing
inositol phosphatase (10). CEACAM1 is characterized by
homophilic adhesion between N-domains of CEACAM1
and likely other CEACAM family members (11) and het-
erophilic interactions with several types of bacteria and vi-
ruses (8, 12–14). These interactions are likely linked to
cell signaling leading to regulation of cell growth and dif-
ferentiation (15–17).
CEACAM1 is also expressed on human and mouse T
cells (18) early after activation (18–22). Ligation of the
N-domain of CEACAM1 with either CEACAM1-specific
mAbs or bacterial products either significantly suppresses or
activates T cells in vitro (18, 20–22). The explanation for
their discrepant functional effect remains unknown. It has
been hypothesized that the inhibition observed might be re-
lated to expression of long cytoplasmic tail isoforms of
CEACAM1, which contain two ITIMs in mouse and hu-
man T cells (3, 21). However, there is no available in vivo
evidence that either supports a role for CEACAM1 in regu-
lating T cell–mediated inflammatory processes and the con-
sequences (inhibition or activation) of ligating CEACAM1
in the setting of inflammation, or the ligands involved.
Therefore, we examined the effects of CEACAM1
 
a 
 
liga-
tion either in vivo with a CEACAM1
 
a
 
-specific mAb and a
homophilic ligand for CEACAM1
 
a 
 
(CEACAM1
 
a
 
-Fc fusion
protein) in the trinitrobenzene sulfonic acid (TNBS) and
oxazolone colitis models (23–25) or in vitro with a hetero-
philic ligand for CEACAM1
 
a
 
, the mouse hepatitis virus
(MHV) spike glycoprotein. Through these studies, we have
linked CEACAM1 to specific regulation of Th1 pathways
and their immunopathologic consequences.
 
Materials and Methods
 
Mice.
 
5–8-wk-old female C57BL/6 and BALB/c mice were
obtained from Charles River Laboratories or the central breeding
facility at the University of Mainz, respectively. IFN-
 
  
 
and IL-4
gene–deficient mice on the C57BL/6 background were pur-
chased from The Jackson Laboratory. Mice were provided sterile
food and water ad libitum, kept in microisolator cages, and main-
tained in the animal facility of Harvard Medical School. All stud-
ies were performed under approval of the Harvard Medical
School Standing Committee on Animals or the ethical commit-
tee of Rheinland-Pfalz.
 
Induction of Hapten-induced Colitis.
 
To generate a more
chronic T cell–mediated inflammation as previously described
(26, 27), mice were sensitized with 150 
 
 
 
l of the haptenating
agent TNBS (2, 4, 6-TNBS; Sigma-Aldrich) at a concentration
of 2.5% in 50% ethanol by skin painting on day 1. On day 8, 150
 
 
 
l of 1% TNBS in 50% ethanol was administered intrarectally via
a 3.5F catheter under anesthesia with tribromoethanol. To ensure
distribution of the TNBS within the entire colon and cecum,
mice were held in a vertical position for 1 min after the in-
stillation. Oxazolone colitis was induced by sensitizing mice
with oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one;
Sigma-Aldrich) at a concentration of 3% in 100% ethanol by skin
painting on day 1 followed by intrarectal administration at a con-
centration of 1% in 50% ethanol on day 8 as described above. On
day 12, mice were killed and immunopathologic characterization
was performed as previously described (23, 26, 27).
 
In Vivo Treatment with CC1 mAb, Anti–IL-4 mAb, and
CEACAM1-Fc Fusion Protein.
 
Anti-CEACAM1
 
a 
 
mAb, CC1,
was purified from a hybridoma derived by fusion of SP20 cells
with spleen cells from SJL/J mice immunized with purified
BALB/c intestinal brush border membranes. Control mouse
IgG1 mAbs directed against irrelevant antigen (the B subunit of
cholera toxin) were purified by standard methods (28–31). Either
1 mg of the CC1 or control mouse IgG1 mAb was administered
24 h before skin painting and/or rectal challenge with the hapte-
nating reagent. Anti–IL-4 mAb was produced from the 11B11
hybridoma cell line (25) and a control rat IgG antibody was ob-
tained from Sigma-Aldrich. C57BL/6 mice with oxazolone coli-
tis were injected with 200 
 
 
 
g/dosage N-CEACAM1-Fc (32) ev-
ery other day starting 1 d before skin painting and ending 1 d
before killing the mice.
 
Flow Cytometry.
 
Single cell suspensions of mononuclear cells
prepared from mesenteric lymph nodes and colonic lamina pro-
pria were stained with either the CC1 or murine IgG1 isotype
control mAb for the primary Ab and FITC-conjugated rat anti–
mouse IgG1 (BD Biosciences) for the secondary Ab. The cells
were costained with PE anti-CD3 mAb (BD Biosciences) and
histograms of CD3
 
  
 
cells were analyzed by FACSort™ (Becton
Dickinson) with CELLQuest™ software (Becton Dickinson).
 
Grading of Histologic Changes.
 
Colonic tissues were removed
on day 12 and embedded in paraffin for staining with hematoxy-
lin and eosin. The degree of inflammation on microscopic cross
sections of the colon was graded semiquantitatively. For the his-
topathologic grading of TNBS-induced colitis, the severity of
colitis was assessed based on two criteria, inflammation and in-
jury. Inflammation was graded from 0 to 4 (0, none; 1, low; 2,
moderate; 3, high; 4, severe with transmural leukocyte infiltra-
tion, loss of goblet cells) and severity of injury was graded from 0
to 3 (0, none; 1, occasional epithelial lesion; 2, clear-cut ulcer-
ation; 3, extensive ulceration). For histopathologic grading of ox-
azolone-induced colitis, five criteria (hypervascularization, pres-
ence of mononuclear cells, epithelial hyperplasia, epithelial
injury, and presence of granulocytes) were scored from 0 to 3 in
each with an additive score between 0 (no colitis) and 15 (maxi-
mal colitis activity). Grading was performed in a blinded fashion
by the same pathologist (J.N. Glickman).
 
Cytokine Assays.
 
Lamina propria mononuclear cells (5 
 
  
 
10
 
5
 
cells/well) isolated on day 12 were stimulated with 5 
 
 
 
g/ml
plate-bound hamster anti–mouse CD3
 
  
 
mAb (BD Biosciences)
and 2 
 
 
 
g/ml soluble hamster anti–mouse CD28 mAb (BD Bio-
sciences). Culture supernatants were harvested 48 h after the cell 
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culture and concentrations of IFN-
 
 
 
, IL-2, IL-4, and TNF-
 
 
 
were measured with OptEIA ELISA sets (BD Biosciences).
 
Isolation of Nuclear Proteins.
 
Spleen mononuclear cells were
washed twice in cold PBS and resuspended in 500 
 
 
 
l buffer A
(10 mM Hepes, 1.5 mM MgCl
 
2
 
, 19 mM KCl, 0.5 mM PMSF, 1
mM DTT) followed by the addition of 20 
 
 
 
l Triton X-100
(Sigma-Aldrich) and incubation on ice for 5 min. Cells were cen-
trifuged for 10 min at 4
 
 
 
C followed by the resuspension of the
nuclear pellet in buffer C (20 mM Hepes, 1.5 mM MgCl
 
2
 
, 0.2
mM EDTA, 25% glycerol, 0.5 mM PMSF, 1 mM DTT). Finally,
the nuclei were homogenized using mini-stir bars for 1 h at 4
 
 
 
C
followed by centrifugation at 15,000 RPM for 15 min at 4
 
 
 
C.
The concentration of nuclear proteins in supernatants was as-
sessed using the Bio-Rad Protein Assay.
 
Western Blots.
 
Equal amounts of extract were added to 8 
 
 
 
l
electrophoresis sample buffer (Firma Roth). After boiling, the ex-
tracts were loaded on 15% SDS-PAGE gels and electrophoretically
 
separated. Proteins were transferred to nitrocellulose membranes
and detection was performed with the ECL Western blotting anal-
ysis system (Amersham Biosciences). Western blots were made us-
ing the following antibodies: rabbit anti–T-bet antibody (1:1,000
dilution; provided by L.H. Glimcher, Harvard School of Public
Health, Boston, MA; reference 33), anti–human signal transducer
and activator of antigen 4 (STAT-4; 1:500 dilution; Santa Cruz
Biotechnology, Inc.), and horseradish peroxidase–linked secondary
antibodies (1:5,000 dilution; Amersham Biosciences).
 
Preparation of CD11c
 
  
 
Cells and IL-12 p70 Cytokine Assay.
 
CD11c
 
  
 
cells were isolated from the spleens of C57BL/6 mice
injected with Flt-3 ligand–bearing B16-F10 melanoma cell line
by using the MACS CD11c microbeads (Miltenyi Biotec) as
previously described (34). The percentage of CD11c
 
  
 
cells was
 
 
 
95% after the purification. For the analysis of IL-12 p70 pro-
duction, cells were stimulated in vitro with 1 mg/ml LPS
(Sigma-Aldrich) and 10 U/ml recombinant mouse IFN-
 
 
 
. Pro-
Figure 1. Effect of CC1 mAb
injection on the induction of TNBS
colitis and cytokine production. (a)
Body weight of mice subjected to
TNBS colitis treated either with
control IgG1 mAb ( ), with CC1
mAb before skin painting and before
rectal challenge twice ( ), before
skin painting ( ), or before rectal
challenge ( ) in C57BL/6 mice are
shown. One group was injected with
50% ethanol ( ) instead of TNBS.
Data are shown as mean values  
SEM and represent eight mice per
group. (b) Macroscopic pictures of
colons from mice induced with
TNBS colitis treated with or without
CC1 mAb are shown. (c) Hematox-
ylin and eosin–stained pictures from
TNBS colitis treated with or without
CC1 mAb are shown ( 100). One
representative picture from each
group of eight is shown. A, control
mAb; B, CC1 mAb administered
twice; C, CC1 mAb administered
before skin painting; D, CC1 mAb
administered before rectal challenge.
(d) Quantitative histopathologic assess-
ment of TNBS colitis activity shows
a significant (*, P   0.05 by t test)
suppression in mice treated with
CC1 mAb either twice or before
rectal challenge when compared
with the control mAb–treated
group. Samples were collected from
mice with TNBS colitis treated either
with control mAb (solid bar) or
CC1 mAb twice (open bar) before
skin painting (shaded bar) or before
rectal challenge (striped bar). Data
are shown as mean values   SEM
and represent eight mice per group.
(e) Th1 and Th2 cytokine production
from LPLs was analyzed by ELISA.
Samples were collected from mice with TNBS colitis treated either with control mAb (solid bars) or CC1 mAb twice (open bars) before skin painting
(shaded bars) or before rectal challenge (striped bars). One group of mice was administered ethanol without TNBS for the skin sensitization and rectal
challenge (hatched bars). CC1 mAb–treated group treated either twice or before rectal challenge exhibited significant suppression of IFN-  production
when compared with the control mAb–treated group (**, P   0.01). Data are shown as mean values   SEM and represent pooled values from eight
independent experiments. 
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duction of IL-12 p70 was measured with OptEIA ELISA sets
(BD Biosciences).
 
In Vitro Differentiation Assay.
 
CD4
 
  
 
CD62L
 
  
 
naive T cells
were isolated from spleens and mesenteric lymphocytes by naive
T cell column kit (R&D Systems). For generation of Th1 cells,
CD4
 
  
 
CD62L
 
  
 
cells were incubated with 1 
 
 
 
g/ml anti-CD3
mAb, 1 
 
 
 
g/ml anti-CD28 mAb, 5 ng/ml recombinant IL-12
(R&D Systems), and 5 
 
 
 
g/ml anti–IL-4 mAb (BD Biosciences)
for 72 h. To generate Th2 cells, CD4
 
  
 
CD62L
 
  
 
cells were incu-
bated with 1 
 
 
 
g/ml anti-CD3 mAb, 1 
 
 
 
g/ml anti-CD28 mAb,
50 ng/ml recombinant IL-4 (R&D Systems), 1 
 
 
 
g/ml anti–IL-12
mAb (BD Biosciences), and 10 
 
 
 
g/ml anti–IFN-
 
  
 
mAb (BD
Biosciences) for 72 h. After 72 h of incubation, the cells were ex-
tensively washed to remove the recombinant cytokines added in
culture and restimulated in vitro with 5 
 
 
 
g/ml anti-CD3 and 5
 
 
 
g/ml anti-CD28 for 48 h. The culture supernatants were sub-
jected to cytokine analysis by ELISA. Several concentrations of
MHV spike glycoprotein (A59S1) or bovine serum albumin (0,
0.1, and 1.0 
 
 
 
g/ml) together with or without antiserum to 100
 
 
 
g/ml of the spike glycoprotein were added during or after the
differentiation to Th1- or Th2-type cells.
 
Statistical Analysis.
 
Statistical analysis was performed using the
Student’s 
 
t
 
 test and the program Microsoft Excel.
 
Online Supplemental Material.
 
Fig. S1 shows induction of ox-
azolone colitis in IFN-
 
 
 
– and IL-4–deficient mice. Fig. S2 shows
histograms of CEACAM1
 
a
 
 expression on CD3
 
 
 
 cells in mesen-
teric lymph node and colonic lamina propria isolated before and
immediately after skin painting, and 24 and 72 h after rectal ad-
ministration with TNBS. Figs. S1 and S2 are available at http://
www.jem.org/cgi/content/full/jem.20030437/DC1.
 
Results
 
Anti-CEACAM1
 
a 
 
mAb, CC1, Protects Mice from TNBS
Colitis When Administered Before the Effector Phase in As-
sociation with Specific Reduction in IFN-
 
  
 
Production.
 
CEACAM1 is known to be expressed constitutively by
murine and human DCs and to be an early activation anti-
gen on human and mouse T cells that may persist for up to
1 wk after activation (3, 18–22). However, little is known
about ligation of CEACAM1 on these cell types in vivo.
Therefore, we assessed whether ligation of CEACAM1
with an anti-CEACAM1–specific mAb CC1, which is di-
rected against the NH
 
2
 
-terminal domain of CEACAM1
 
a
 
,
affected the course of TNBS colitis, a model mediated pri-
marily by Th1 cytokines in certain strains of mice (23). To
test whether CEACAM1
 
a 
 
is involved in T cell–mediated
colonic inflammation at the time of T cell priming by DCs
or at the time of the effector response by intestinal T cells,
we assessed the effects of CC1 mAb at the time of either T
cell priming (before skin painting) and/or the effector
phase (before rectal challenge) in the TNBS colitis model.
Animals that received TNBS in association with either a
control mAb (Fig. 1 a, 
 
 
 
) or the CC1 mAb before skin
painting (Fig. 1 a, 
 
 
 
) experienced severe weight loss. In
contrast, mice that received the CC1 mAb either before
rectal challenge (Fig. 1 a, 
 
 
 
) or both skin painting and
rectal challenge twice (Fig. 1 a,  ) experienced less weight
loss. This was directly reflected in the levels of macro-
scopic injury observed in that mice treated with the CC1
mAb either before rectal challenge or twice did not ex-
hibit significant shortening and thickening of the colon
(Fig. 1 b). Consistent with these macroscopic changes, the
control mAb–treated group and groups receiving the CC1
mAb only before skin painting exhibited marked, trans-
mural infiltration with inflammatory cells and injury with
ulceration (Fig. 1 c, A and C, respectively). In contrast,
mice treated with the CC1 mAb either twice or before
rectal challenge exhibited less severe histologic features of
colitis (Fig. 1 c, B and D, respectively). When quantified
by a histologic scoring system for evidence of inflamma-
tion and injury, these histologic challenges were highly
significant (Fig. 1 d).
To determine whether this mAb CC1-mediated protec-
tion from colitis was associated with alterations in cytokine
production, Th1 (IFN- , IL-2, TNF- )– and Th2 (IL-4)–
associated cytokine production by lamina propria lympho-
cytes (LPLs) was assessed in the various treatment groups.
These studies revealed a significant reduction in IFN- 
production by LPLs from mice that received the CC1 mAb
either before rectal challenge or twice, but not under the
other conditions examined (Fig. 1 e). Interestingly, no ef-
fects were observed on IL-2, TNF- , and Th2 cytokine
production as defined by assessment of IL-4. A similar inhi-
bition of IFN-  but not IL-4 as a consequence of CC1
mAb treatment was observed with splenocytes stimulated
with anti-CD3 plus anti-CD28 mAbs (unpublished data).
Moreover, the quantities of CD4  T cells within the lam-
ina propria did not differ between CC1-treated and un-
treated animals, indicating that the effects observed were
not simply due to decreased T cells in this compartment
(unpublished data). These results indicate that suppression
of TNBS colitis by administration of the CC1 mAb is asso-
ciated with a specific reduction in production of IFN-  but
not IL-4, which is consistent with the role of IFN-  in this
model of colitis (23).
Anti-CEACAM1a mAb CC1 Also Protects Mice from
Oxazolone Colitis When Administered Before the Effector
Phase in Association with Reduction in IFN- . To determine
whether these effects of CEACAM1 on the development
of T cell–mediated immunopathology in the colon could
be extended to a Th2-associated colitis, we next analyzed
the effect of the CC1 mAb in the oxazolone colitis model,
which has been previously shown to be primarily Th2 me-
diated in the SJL strain of mice (25). The same general ef-
fects of CC1 mAb on TNBS colitis on the body weight
were also evident in oxazolone colitis (Fig. 2 a). Specifi-
cally, mice treated with the CC1 mAb either before rectal
challenge (Fig. 2 a,  ) or twice (Fig. 2 a,  ) and, to a lesser
extent, before skin painting (Fig. 2 a,  ) exhibited less
weight loss than mice treated with the control mAb (Fig. 2
a,  ). An assessment for macroscopic evidence of colon
shortening confirmed these clinical findings (Fig. 2 b). His-
tologic analysis also revealed that colon tissues from mice
treated with the CC1 mAb either twice or before rectal
challenge exhibited significantly less severe histologic evi-
dence of colitis (Fig. 2 c, B and D, respectively). In con-Iijima et al. 475
trast, the control mAb–treated mice or mice treated with
CC1 mAb before skin sensitization developed severe colitis
(Fig. 2 c, A and C, respectively). When analyzed quantita-
tively with a scoring system previously applied to this
model, these differences were highly significant (Fig. 2 d).
The oxazolone colitis model was originally reported to
be a predominantly Th2-mediated model in SJL mice (25).
These results were therefore interesting in that they would
have predicted that CEACAM1 was regulating Th2 path-
ways. Quite surprisingly, however, when the cytokines
Figure 2. Effect of CC1 mAb in-
jection on the induction of oxazolone
colitis and cytokine production. (a)
Oxazolone colitis was induced in
C57BL/6 mice and mice were mon-
itored for body weight after various
combinations of treatments with
CC1 or control mAb. Mice were
treated either with control IgG1
mAb ( ), with CC1 mAb twice
( ), before skin painting ( ), or
before  rectal challenge ( ). One
group was subjected to intrarectal
administration with 50% ethanol ( )
instead of oxazolone. Data are
shown as mean values   SEM and
represent eight mice per group. (b)
Macroscopic pictures of oxazolone
colitis treated with or without CC1
mAb. (c) Histologic hematoxylin
and eosin–stained pictures from ox-
azolone colitis treated with or without
CC1 mAb are shown ( 100). One
representative picture from each
group of eight is shown. A, control
mAb; B, CC1 mAb administered
twice; C, CC1 mAb administered
before skin painting; D, CC1 mAb
administered before rectal challenge.
(d) Quantitative histopathologic assess-
ment of oxazolone colitis activity
shows a significant suppression in
mice treated with CC1 mAb either
twice or before rectal challenge in
comparison to the control mAb–
treated group (*, P   0.01). Samples
were collected from mice with ox-
azolone colitis that were treated either
with control mAb (solid bar) or
CC1 mAb either twice (open bar),
before skin painting (shaded bar), or
before rectal challenge (striped bar).
Data are provided as mean values  
SEM and represent eight mice per
group. V, hyper-vascularization; M,
presence of mononuclear cells; H,
epithelial cell hyperplasia; I, epithelial
injury; G, presence of granulocytes;
T, total score. (e) Th1 and Th2 cy-
tokine production from LPLs was
analyzed by ELISA. Samples were
collected from mice with oxazolone
colitis that were treated either with
control mAb (solid bars) or CC1
mAb either twice (open bars), before skin painting (shaded bars), or before rectal challenge (striped bars). One group of mice was administered ethanol
instead of oxazolone (hatched bars). Mice treated with CC1 mAb either twice or before rectal challenge exhibited significant suppression of IFN- 
production when compared with the control mAb–treated group (*, P   0.01). Data shown represent pooled values from eight independent experiments.
Data are shown as mean values   SEM. (f) Analysis of T-bet and STAT-4 levels in splenic mononuclear cells from mice with oxazolone-induced colitis
upon CEACAM1 ligation. Mice with oxazolone-induced colitis were treated with the CC1 mAb as described above followed by isolation of splenic
cells and extraction of nuclear proteins. Spleen mononuclear cells were stimulated in a T cell–specific fashion with antibodies to CD3 and CD28 for 24 h.
Equal amounts of proteins from two to three mice per group were then subjected to Western blot analysis for expression of STAT-4 and T-bet as indicated.
Samples from 1 through 3 were obtained from mice treated with CC1 mAb and samples from 4 and 5 were obtained from mice treated with control
mAb. T-bet gave two bands by Western blot analysis as previously described (references 27 and 33).CEACAM1 Regulation of Colitis 476
produced by LPLs after anti-CD3 plus anti-CD28 stimula-
tion were analyzed in this model, IFN-  but not the Th2
cytokine (IL-4) was significantly decreased in C57BL/6
mice that received the CC1 mAb either before rectal chal-
lenge or twice (Fig. 2 e). Although TNF-  is crucial in the
induction of Th1-type immune pathways and the patho-
genesis of murine model of inflammatory bowel disease
(35), production of TNF-  was not affected by the CC1
mAb treatment in either TNBS or oxazolone colitis (Figs.
1 e and 2 e). Other regulatory cytokines (e.g., TGF- , IL-
10) and Th1/Th2 cytokines (e.g., IL-2, IL-5, IL-10, IL-13)
were not affected by CC1 mAb treatment in both the
TNBS and oxazolone colitis models (unpublished data).
Thus, as observed in the TNBS colitis model, ligation of
CEACAM1a by the CC1 mAb at the time of the effector
phase of oxazolone-induced colitis caused a decrease in co-
lonic immunopathology that was associated with specific
inhibition of the Th1 cytokine, IFN- , but not Th2 or
regulatory cytokines.
Ligation of CEACAM1 Suppresses IFN-  Signaling via
T-bet but Not STAT-4 Signaling. To determine the effects
of CEACAM1 ligation on Th1 cytokine signaling, we next
determined the expression of signature transcription factors
in spleen cells from mice with oxazolone-induced colitis
upon antibody treatment. Specifically, we analyzed the nu-
clear levels of the transcription factors T-bet and STAT-4
because these transcription factors are essential for IFN- 
(33) and IL-12 signaling (36) in T lymphocytes, respec-
tively. Accordingly, we isolated nuclear proteins from the
spleen cells of oxazolone-treated mice upon administration
of anti-CEACAM1 and control antibodies. As shown in
Fig. 2 f, ligation of CEACAM1 by the CC1 mAb led to a
profound down-regulation of nuclear T-bet expression as
determined by Western blot analysis. In contrast, nuclear
levels of STAT-4 were nearly unaffected suggesting that
CEACAM1 strongly controls IFN-  but not IL-12 signal-
ing in T cells via T-bet.
Deficiency of IFN-  or IL-4 Is Associated with Less Severe
Colon Injury in Response to Oxazolone. Because our results
suggested a novel role for Th1 cytokines in oxazolone coli-
tis in C57BL/6 mice, we investigated further the involve-
ment of Th1 and Th2 cytokines in this model. Given previ-
ous reports that oxazolone colitis was predominantly Th2
mediated, we investigated this issue further by inducing ox-
azolone colitis in IFN- –deficient (IFN-  / ) and IL-4–
deficient (IL-4 / ) mice on a C57BL/6 background. Both
IFN-  /  and IL-4 /  mice were significantly protected
from body weight loss and shortening of the colon when
Figure 3. Effect of anti–IL-4 mAb and
CC1 mAb injection on the induction of
oxazolone colitis. (a) Body weight of mice
treated with anti–IL-4 mAb together with
CC1 mAb ( ), anti–IL-4 mAb and control
mouse IgG1 ( ), or control rat IgG and
mouse IgG1 ( ). Prevention of body
weight loss was significant (*, P   0.05; **,
P   0.01) in mice administered anti–IL-4
and CC1 mAb when compared with the
control Ab–treated group. Data shown are
expressed as mean values   SEM from six
mice per group. Representative macro-
scopic (b) and microscopic (c;  100) pictures
of mice treated with or without anti–IL-4
and CC1 mAbs are shown.Iijima et al. 477
compared with wild-type mice that were treated similarly
(Fig. S1, a and b, available at http://www.jem.org/cgi/
content/full/jem.20030437/DC1). Consistent with these
effects, histologic analyses showed that both IFN-  /  and
IL-4 /  mice exhibited less severe but still mild colitis com-
pared with wild-type mice (Fig. S1 c, available at http://
www.jem.org/cgi/content/full/jem.20030437/DC1). The
average colitis scores of wild-type, IFN-  / , and IL-4 / 
mice were 7.2, 2.4, and 4.0, respectively. Notably, although
the colitis scores of the IFN-  /  and IL-4 /  mice were
significantly lower than that of the wild-type mice (P  
0.01 and P   0.05, respectively), colitis was still present. An
analysis of cytokines produced by LPLs showed that there
was no difference in the levels of cytokines (IFN- , IL-2,
IL-4, and IL-5) except those depleted by the gene targeting
(unpublished data). A similar reduction in the severity of
colitis was observed in IFN-  /  mice on a BALB/c back-
ground (unpublished data). These results indicate that both
IFN-  and IL-4 play independent and additive roles in the
induction of oxazolone colitis in both the C57BL/6 and
BALB/c backgrounds.
Administration of CC1 mAb Together with Anti–IL-4 mAb
Enhances the Protection of Mice from Oxazolone Colitis. The
studies described above suggested that CEACAM1a ligation
specifically impacts upon Th1 but not Th2 pathways in
these models. Given that oxazolone colitis represents a
mixed Th1/Th2 colitis in C57BL/6 mice as shown above,
we examined the effects of administering the CC1 mAb
and/or anti–IL-4 mAb to inhibit both Th1 and Th2 path-
ways, respectively. If oxazolone colitis was indeed due to
both Th1 and Th2 cytokines and CEACAM1a was specific
for the Th1 pathway, it would be predicted that more
complete clinicopathologic protection would be provided
by blocking both pathways. Protection as defined by body
weight loss was nearly complete when mice received treat-
ment with an anti–IL-4 mAb in combination with the
CC1 mAb (Fig. 3 a,  ) in comparison to either the control
Ab–treated (Fig. 3 a,  ) or anti–IL-4– and control Ab–
treated (Fig. 3 a,  ) groups. Notably, an essential role for
IL-4 in this model was suggested by the fact that blockade
of IL-4 either alone or together with CEACAM1a ligation
via treatment with the CC1 mAb afforded significant mac-
roscopic protection in comparison to the control rat IgG
and mouse IgG1–treated group (Fig. 3 b). Microscopic
analysis clearly supported a role for both IL-4 and IFN-  in
the pathogenesis of oxazolone colitis and a specific role for
CEACAM1a in IFN-  regulation. Specifically, treatment
with the anti–IL-4 mAb with or without the CC1 mAb re-
sulted in less severe histologic features of colitis compared
with the control group (Fig. 3 c). However, the greatest
protection from histologic injury was provided by a combi-
nation of the CC1 and IL-4 mAbs because the mean colitis
score of this group was 3.8 in comparison to scores of 5.0
and 11.3 for the anti–IL-4 plus control and control Ab–
treated groups, respectively (P   0.01, anti–IL-4 and CC1
mAb vs. control mAbs; P   0.05, anti–IL-4 plus mouse
IgG1 mAb vs. control mAbs). In addition, anti–IL-4 and
CC1 mAb treatment, but not either alone, suppressed the
levels of both IFN-  and IL-4 to baseline levels in the co-
lonic lamina propria in the context of oxazolone colitis
(unpublished data). These results confirm that oxazolone
colitis is caused by both Th1 and Th2 cytokine pathways
such that blockade of both provides optimal protection
from clinical evidence of colitis and immunopathology,
and that CEACAM1a is specifically linked to Th1 pathways
allowing for an enhancement of the protective effect pro-
vided by anti–IL-4 mAb treatment.
Neither In Vivo nor In Vitro Treatment with the CC1 mAb
Affects IL-12 p70 Production. These studies indicate that
CEACAM1a ligation by the CC1 mAb in vivo specifically
inhibits IFN-  during the course of T cell–mediated intes-
tinal inflammation. One possible mechanism to explain this
result is through CEACAM1a regulation of IL-12 produc-
tion given that IFN-  production from Th1 cells is regu-
lated by IL-12 p70 produced by APCs (e.g., DCs, macro-
phages; references 37 and 38). In addition, it has been
previously reported that CEACAM1a ligation on mouse
DCs in vitro results in IL-12 release and thus promotion of
IFN-  production (3). Thus, we assessed IL-12 production
in the TNBS colitis model. IL-12 p70 production by
spleen (unpublished data) and lamina propria cells from
mice exposed to TNBS was not affected by in vivo treat-
ment with the CC1 mAb (control mAb, 317.5   59.3 pg/
ml; CC1 mAb twice, 400.3   82.1 pg/ml; CC1 mAb pre-
skin, 280.3   57.5 pg/ml; CC1 mAb pre-rectal, 415.3  
86.3 pg/ml; not significant). In addition, IL-12 p70 pro-
duction by CD11c  DCs stimulated with LPS and IFN- 
in vitro was not significantly altered by treatment with the
CC1 mAb in comparison to an isotype control mAb (un-
published data). Thus, inhibition of IFN-  production by
treatment with the CC1 mAb was not likely to effect IL-12
p70 production by APCs including DCs.
CEACAM1a Chimeric Protein Prevents Oxazolone Colitis
and Suppresses IFN-  Production. Our results, as shown
here, indicate that ligation of CEACAM1a with the CC1
mAb significantly suppresses colitis in association with inhi-
bition of T cell production of IFN-  by LPLs. However,
these results do not define either the nature of the natural
ligand for CEACAM1a in vivo and whether inhibition of
Th1-mediated immunopathology can be caused by ligation
of CEACAM1a with its natural ligand. To define the ligand
for CEACAM1a in vivo, we examined the effects of a
CEACAM1a-Fc fusion protein (sMHVR-Ig) encoding the
extracellular portion of the mCEACAM1a-4L isoform that
has been shown to homophilically ligate the CEACAM1a
molecule in vitro (32). Therefore, mice were treated with
either the CEACAM1a-Fc fusion protein or a control iso-
type–matched Fc fragment at a dose of 200  g adminis-
tered every other day for seven doses beginning at the time
of skin sensitization in the oxazolone colitis model. Macro-
scopic assessment revealed that shortening of the colon was
less severe in the mice treated with CEACAM1a-Fc com-
pared with the mice administered the control-Fc fragment
(Fig. 4 a). Similarly, histologic evidence of colitis was lessCEACAM1 Regulation of Colitis 478
pronounced in the CEACAM1a-Fc–treated group com-
pared with the control-Fc–treated group (Fig. 4, b and c).
These pathologic findings were associated with a significant
decrease in IFN-  production by LPLs from mice treated
with the CEACAM1a-Fc fusion protein (Fig. 4 d). The fact
that the decrease in immunopathologic injury observed oc-
curred in association with suppression of IFN-  production
indicated that these were causally related.
Ligation of CEACAM1a on T Cells Specifically Inhibits the
Differentiation and Activation of Th1 Cells In Vitro. The ob-
servations described above suggest that homophilic ligation
of CEACAM1a in vivo during the effector phase of colitis
induces an inhibitory pathway associated with down-regu-
lation of IFN-  production. Given the absence of an effect
of the CC1 mAb on IL-12 production, we reasoned that li-
gation of CEACAM1a on a T cell might mediate this re-
sponse. To determine this, we first examined the expres-
sion of CEACAM1a on CD3  cells during the course of
TNBS colitis as defined by flow cytometry. As predicted
by in vitro studies showing that CEACAM1a is an activa-
tion antigen on mouse and human T cells (18, 19, 21, 22),
we observed that a small proportion ( 5%) of T cells ex-
pressed CEACAM1a within mesenteric lymph nodes and
LPLs in the normal intestine, presumably consistent with
the physiologic inflammation that is normally ascribed to
this organ system (Fig. S2, available at http://www.jem.
org/cgi/content/full/jem.20030437/DC1). By 4 d after
induction of colitis induced by TNBS administration,
CEACAM1a continued to be detectable on a similar but
unchanged proportion of CD3  LPLs (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20030437/DC1).
Similar observations were made at various other time
points after TNBS administration and after induction of
colitis with oxazolone administration (unpublished data),
indicating that CEACAM1a is expressed in vivo in T cells
during intestinal inflammation and amenable to ligation
with CEACAM1a-related ligands.
Next, we sought to directly address whether ligation of
CEACAM1a regulates IFN-  production by T cells. Naive
T cells were differentiated and activated into either Th1 or
Th2 cells in the presence of a natural CEACAM1a ligand that
binds within the homophilic binding site of the N-domain.
For this purpose, a his-tagged version of the MHV spike
glycoprotein was added during the differentiation and acti-
vation of either Th1 or Th2 cells (39). We used the MHV
spike glycoprotein due to nonspecific effects of either con-
trol-Fc fragments or IgG antibodies in the model system
used that prevented interpretation of similar studies with
either the CEACAM1a-Fc fusion protein or the CC1 mAb
(unpublished data). IFN-   production was significantly
suppressed in a dose-dependent fashion by addition of the
spike glycoprotein during the differentiation of naive T
cells into Th1 cells (Fig. 5 a). Addition of the spike glyco-
protein also inhibited the production of IFN-  by differen-
Figure 4. Effect of
CEACAM1-Fc chimeric protein
on the induction of oxazolone
colitis. Macroscopic (a) and his-
tologic pictures (b;  100) of
colon isolated from mice induced
to develop oxazolone colitis
treated with CEACAM1-Fc or a
control-Fc fragment. (c) Colitis
scores of colon-induced ox-
azolone colitis treated with
CEACAM1-Fc (solid bar) or a
control-Fc fragment (open bar).
Mice treated with CEACAM1-
Fc exhibited significant reduction
in colitis scores (*, P   0.005; **,
P   0.01). V, hyper-vasculariza-
tion; M, presence of mononuclear
cells; H, epithelial cell hyperplasia;
I, epithelial injury; G, presence
of granulocytes; T, total score.
(d) Th1 and Th2 cytokine pro-
duction from LPLs was analyzed
by ELISA of mice with ox-
azolone colitis treated either
with CEACAM1-Fc (solid bars)
or control-Fc fragment (open
bars). Suppression of IFN-  was
significant (**, P   0.01). Data
are shown as mean values  
SEM from four independent
experiments.Iijima et al. 479
tiated Th1 cells (Fig. 5 b). The inhibition of IFN-  pro-
duction was completely reversed by addition of a blocking
antibody specific for the viral spike glycoprotein and was
not observed when similar concentrations of bovine serum
albumin were added as controls (Fig. 5, a and b). In con-
trast, ligation of CEACAM1a by the spike glycoprotein had
no effect on the differentiation and activation of IL-4–pro-
ducing Th2-type cells (Fig. 5, c and d). These results show
that ligation of CEACAM1a on the cell surface of T cells by
a ligand that naturally binds to the homophilic interaction
site of the N-domain causes specific inhibition of Th1 dif-
ferentiation and cytokine production.
Discussion
These studies identify a novel role for CEACAM1a in
regulating T cell–dependent immunopathology in vivo
based upon an analysis of two different types of murine coli-
tis models, i.e., TNBS and oxazolone colitis, and link this
directly with specific inhibition of Th1 pathways and Th1
cytokine signaling. Both of these colitis models are induced
by haptenating reagents that induce activation of haptenated
antigen-specific T cells (23, 40). The TNBS colitis model
has been reported to be specifically mediated by Th1 cyto-
kines in most mouse strains (23, 41). Thus, our studies that
have revealed that ligation of CEACAM1a with an anti-
CEACAM1a–specific mAb (CC1) could protect against the
development of TNBS colitis in association with specific re-
duction in IFN-  production by LPLs strongly suggest that
the diminution in immunopathology caused by the CC1
mAb is due to inhibition of Th1 pathways.
The reason for the specific down-regulation of Th1 cy-
tokines and in particular IFN-  by CEACAM1a ligation
was determined in subsequent studies. Although it has been
previously reported that cross-linking of CEACAM1a on
mouse DCs by another mouse CEACAM1a-specific mAb
AgB10 induces Th1 cytokine production via the release of
IL-12 from DCs (3), we did not observe any effects of the
CC1 mAbs on IL-12 production by CD11c  cells stimu-
lated in vitro. In addition, we observed no difference in the
levels of IL-12 produced by spleen and lamina propria
mononuclear cells from mice stimulated ex vivo in which
TNBS colitis had been induced in the presence of the CC1
mAb. Moreover, treatment of mice with the CC1 mAb
before skin sensitization, when T cell priming by DCs oc-
curs and IL-12 production is likely to be maximally in-
duced by DC–T cell interactions involving CD40 and
CD40L for example (42), did not significantly impact the
severity of colitis or Th1 (IFN- ) cytokine production.
This differs from a previous report from our group that
CEACAM1a ligation inhibits a delayed-type hypersensitiv-
ity response in the skin more so when performed during
the phase of T cell priming and is consistent with our in
vitro results with CEACAM1a ligation (18). The reason for
these differences is unclear but may represent at its simplest
variations between CEACAM1a function in the skin and
gut. In contrast, given that administration of the CC1 mAb
before the secondary exposure with antigen during the ef-
fector phase had major effects upon TNBS-associated im-
munopathology and Th1 (IFN- ) cytokine production as
reported here at a time when antigen-specific T cells have
been activated and are presumably expressing significant
Figure 5. CEACAM1a-mediated
inhibition of T cells. Naive T cells
isolated from C57BL/6 mice were
stimulated in vitro with anti-CD3
mAb and anti-CD28 mAb under
Th1-inducing conditions (a and b)
or Th2-inducing (c and d) condi-
tions. Different concentrations of the
MHV spike glycoprotein with or
without antisera to the anti-MHV
spike glycoprotein were added in the
culture during (a and c) or after (b and
d) the differentiation to Th1/Th2
cells. Production of IFN-  was sig-
nificantly suppressed by the spike
glycoprotein when added during
and after the differentiation to Th1
(*, P   0.05) but not Th2 cells.  ,
BSA;  , spike protein plus control
serum;  , spike protein plus antisera
to spike glycoprotein. Data are shown
as mean   SEM and are representa-
tive of three separate experiments.CEACAM1 Regulation of Colitis 480
levels of CEACAM1a (2, 19–21), an alternative explana-
tion is possible. Specifically, our observation that a
CEACAM1a-Fc fusion caused a reduction in IFN-  pro-
duction and associated immunopathology suggests that ho-
mophilic ligation of CEACAM1 on antigen-activated T
cells leads to induction of an inhibitory pathway in T cells
that is specifically linked to Th1 pathways. These studies
thus suggest that CEACAM1a on activated T cells might be
the target of the CC1 mAb. Although it is possible that the
CC1 mAb mediates its effects in the TNBS model through
interactions with other cell types that are known to express
CEACAM1a such as macrophages, B cells, NK cells, and
epithelial cells (3–7), as the TNBS colitis model is clearly
regulated by Th1 pathways, the CC1 mAb induced down-
regulation of IFN-  production by T cells is likely to play
an indispensable role in the suppression of the colitis ob-
served. Moreover, the fact that production of Th2 cyto-
kines was not affected by the CC1 mAb in the TNBS coli-
tis model further suggests that CEACAM1a is directly and
specifically linked to regulation of Th1 but not Th2 path-
ways in this model. Furthermore, the result that the MHV
spike glycoprotein, which binds to the N-domain of
CEACAM1a, specifically inhibited Th1 differentiation and
activation by purified T cells directly supports a role for
CEACAM1a regulating Th1 cytokine production by T
cells. Taken together with the observation that a chimeric
CEACAM1-Fc fusion, which is known to bind homophil-
ically to CEACAM1a, could also reduce immunopathology
and Th1 cytokine production in vivo, our results suggest
that homophilic (CEACAM1a) or heterophilic (MHV or
antibody) ligation of CEACAM1a can directly activate an
inhibitory pathway on T cells that is linked to Th1 cyto-
kine production. Preliminary observations that overexpres-
sion of a long cytoplasmic tail isoform of CEACAM1a in
naive mouse T cells inhibits the development of colitis and
IFN-  production after transfer into RAG-deficient recipi-
ent mice directly supports this proposed mechanism of in-
hibition (unpublished data).
Because CEACAM1 ligation had no significant effect on
IL-12 production that could account for suppression of
Th1 T cell activity in colitis, we analyzed the expression
and activation of Th1-associated transcription factors. In-
terestingly, a marked suppression of nuclear levels of T-bet,
a master transcription factor for Th1 cells, was noted upon
CEACAM1 ligation, whereas the levels of the IL-12–
inducible transcription factor STAT-4 showed little or no
change. These data suggest that CEACAM1 controls Th1
T cell activation and Th1-mediated immunopathology in
vivo via its effects on T-bet. Blockade of CEACAM1 liga-
tion in vivo may in turn suppress Th1 T cell activation via
down-regulation of T-bet and its effects on chromatin re-
modeling and promoter activity in the IFN-  gene locus
(33, 43). The molecular basis for the effects of CEACAM1
on T-bet activation, however, remains to be defined. Fur-
thermore, based upon the fact that human and mouse T
cells express CEACAM1a isoforms containing a long cyto-
plasmic tail known to associate with SHP-1 when phos-
phorylated (18, 21, 22, 44), CEACAM1a ligation may in-
duce negative signals provided by the ITIM-containing
cytoplasmic tail of CEACAM1a. Although this remains to
be proven, in preliminary support of this possibility, we
have observed that transfection of a long but not short cy-
toplasmic tail containing isoform of CEACAM1 into hu-
man T cells results in inhibition of T cell receptor–CD3
complex signaling, which is dependent upon both ITIM
domains and SHP-1 (unpublished data).
Ligation of a similar immune inhibitory receptor con-
taining an ITIM, programmed death 1, down-regulates
both Th1 and Th2 cytokines with the effect upon Th1 cy-
tokines being larger than that on Th2 cytokines (45). Our
data showing that ligation of CEACAM1 specifically inhib-
its IFN-  but not IL-4 in these models are thus unique.
However, it remains possible that like programmed death
1, CEACAM1 may inhibit both Th1 and Th2 pathways if
the signal strength is either of high enough intensity and/or
modified by other pathways.
Another interesting aspect of our study is that the CC1
mAb could also prevent oxazolone colitis via suppression of
IFN-  production by LPLs. This is interesting because ox-
azolone colitis was originally reported as a predominantly
Th2-type colitis model (25). Our studies with IFN-  / 
and IL-4 /  mice clearly indicate that oxazolone colitis is
caused by both Th1 and Th2 cytokines in C57BL/6 and
BALB/c mouse strains. The differences in the results de-
scribed here relative to those previously reported (25)
might be due to differences in the mouse strains used and/
or in the bacterial flora of the animal facility in which the
models were studied. It may also be possible that the con-
tribution of cytokines for the induction of colitis varies
during the course of oxazolone colitis similar to that which
has been previously reported for the TNBS colitis and IL-
10 /  colitis models in which Th1 and Th2 cytokines are
operative during different phases of colitis (46, 47). As
shown here, combination therapy with CC1 and anti–IL-4
mAbs to block both Th1 and Th2 pathways were additive
in preventing oxazolone colitis in C57BL/6 mice. This is
consistent with recent evidence that both Th1 and Th2
cells specific for the same bacterially associated antigen can
drive the progression of colitis (48).
In summary, we have shown that CEACAM1a is associ-
ated with specific regulation of Th1 pathways in vivo as
defined by an analysis of two T cell–dependent, hapten-
mediated colitis models. Based upon an analysis of the ef-
fects of a CEACAM1a-Fc chimeric protein in vivo and a
soluble natural ligand for the N-domain of CEACAM1a
(the MHV spike glycoprotein) on T cells in vitro, the
regulation of Th1 pathways by CEACAM1a is likely
due to either homophilic or heterophilic ligation of the
CEACAM1a N-domain on activated T cells. These results
directly demonstrate an in vivo role for CEACAM1 as a
functionally important activation-induced regulatory mole-
cule on T cells as suggested by previous in vitro studies (3,
4, 18, 20, 21) and show that the major functional effect of
CEACAM1 on T cells in vivo is inhibitory and not stimu-Iijima et al. 481
latory as suggested by some prior in vitro studies (19, 22).
Moreover, these studies point toward an important role for
CEACAM1 in regulating Th1-mediated inflammation
such as that associated with inflammatory bowel disease
and, potentially, virus-mediated immunopathology.
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